In addition, it has been observed that patients with asthma who use ICSs showed less susceptibility to SARS-CoV-2 infection, decreased COVID-19 morbidity and lower ACE2 levels in sputum cells in comparison with asthma patients who were not using ICSs [21]. This evidence concerns the gene ACE2 and COVID-19.